Critical Survey: Iqvia (NYSE:IQV) vs. Biohaven Pharmaceutical (BHVN)

Iqvia (NYSE: IQV) and Biohaven Pharmaceutical (NYSE:BHVN) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of current recommendations for Iqvia and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iqvia 0 6 10 0 2.63
Biohaven Pharmaceutical 0 0 6 0 3.00

Iqvia currently has a consensus price target of $109.91, suggesting a potential upside of 14.85%. Biohaven Pharmaceutical has a consensus price target of $38.67, suggesting a potential upside of 57.63%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher probable upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Iqvia.

Profitability

This table compares Iqvia and Biohaven Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iqvia 13.44% 13.03% 4.65%
Biohaven Pharmaceutical N/A -86.82% -76.51%

Insider and Institutional Ownership

92.3% of Iqvia shares are owned by institutional investors. Comparatively, 61.8% of Biohaven Pharmaceutical shares are owned by institutional investors. 6.0% of Iqvia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Iqvia and Biohaven Pharmaceutical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iqvia $9.74 billion 2.05 $1.31 billion $4.36 21.95
Biohaven Pharmaceutical N/A N/A -$127.19 million ($5.00) -4.91

Iqvia has higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a lower price-to-earnings ratio than Iqvia, indicating that it is currently the more affordable of the two stocks.

Summary

Iqvia beats Biohaven Pharmaceutical on 10 of the 12 factors compared between the two stocks.

Iqvia Company Profile

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply